Upper GI Bleeding
Up to 90 per cent of upper GI bleeding is attributable to peptic ulceration, erosive gastritis, or esophagogastric varices.
Peptic Ulcer. Bleeding may occur from duodenal, gastric, and post-surgical anastomotic ulcers. A typical history of ulcer pain or dyspepsia may be absent, with bleeding being the first manifestation of peptic ulcer disease.
Gastritis. Erosive gastritis may result from ingestion of alcohol or anti-inflammatory drugs, such as aspirin or indomethacin. Gastric erosions also frequently develop as so-called stress gastritis in hospitalized patients with major trauma, severe systemic illness, extensive burns, or head injury. Since the risk of bleeding from erosive gastritis is recognized as being high (about 20 per cent) with a high mortality rate in such severely ill hospitalized patients, preventive measures aimed mainly at raising gastric pH above 4 are usually instituted through the hourly administration of antacids. Although clearly successful in preventing bleeding, these measures do not affect mortality in these critically ill patients.
Esophagogastric Varices. Bleeding occurs most frequently from varices in the esophagus and is characteristically abrupt and massive. Varices arise mainly as a result of portal hypertension secondary to cirrhosis. Alcoholic cirrhosis is by far the commonest cause of variceal bleeding in the United States, although any cause of portal hypertension (e.g., portal venous thrombosis, schistosomiasis) may lead to variceal hemorrhage. Three factors complicate the course of GI bleeding in patients with cirrhosis. (1) Although varices are usually suspected as the cause of bleeding, other causes (e.g., gastritis, ulcers) actually account for up to 50 per cent of bleeding lesions in these patients. These other causes of bleeding must invariably be considered in the diagnostic work-up of the cirrhotic patient. (2) Sustained portal hypertension leads to recurrent bleeding in 70 per cent of patients with cirrhosis. Thus portal decompression by means of a surgically created portosystemic shunt is the only absolutely effective means for preventing recurrence of bleeding. This in turn carries a high morbidity and appreciable mortality, especially when performed as an emergency procedure. (3) Cirrhosis often leads to the development of encephalopathy, which may manifest or exacerbate during bleeding, as well as to the development of coagulation defects, which contribute to continued bleeding. Because of these three factors, GI bleeding in patients with cirrhosis often poses difficult therapeutic problems.
Other Lesions. The Mallory-Weiss syndrome, which refers to hemorrhagic laceration of the mucosa of the esophagogastric junction produced by vomiting, is characterized by a history of retching and nonbloody vomiting followed by hemate-mesis. Several other lesions of the upper GI tract, including esophagitis, carcinoma, and other tumors of the stomach, generally cause chronic blood loss but may also produce massive bleeding. Arterial-enteric fistulae may occur as a result of the use of synthetic bypass grafts for aortic aneurysms and must be suspected in any patient who has had such a bypass and presents with GI bleeding.
- Treatment
- CLINICAL AMD LABORATORY FEATURES
- Bleeding Diatheses
- ADAPTATION TO NEPHRON LOSS
- MOXIOUS GASES AflD FUMES
- Portal Hypertension
- Hepatocellular Carcinoma
- CARCINOMA OF THE PANCREAS - Definition
- Resuscitation
- Elimination of Waste Products of Metabolism and Drugs
- Skin and Conjunctiva
- CLINICAL FEATURES OF PULMONARY HYPERTENSION
- Complications of Dialysis
- Sarcoidosis
- OTHER THERAPEUTIC MODALITIES
- Urinalysis, Renal ‘Tubular Function, and Urine Flow Rate
- CHEST WALL DISEASE
- COMMON PRESENTING COMPLAINTS
- OXYGEN THERAPY AND MECHANICAL VENTILATION
- MYOCARDIAL DISEASE - MYOCARDITIS
- ELECTRICAL CONDUCTION SYSTEM
- TREATMENT
- THE FAMILIAL POLYPOSIS SYNDROMES
- Alterations in Drug Doses in Patients with Renal Failure
- RHEUMATIC FEVER
- PROGNOSIS
- Clinical Manifestations
- CLASSIFICATION OF THE MALABSORPTION SYNDROMES
- RENAL PHARMACOLOGY
- Clinical Manifestations
- CARCINOMA OF THE PANCREAS - Diagnosis
- CHRONIC RENAL FAILURE
- SPECIFIC ENTITIES - DISEASES WITH KFiOWIi ETIOLOGIES -
- Differential Diagnosis and Evaluation of the Patient
- Definition